Dimitri Krainc - Publications

Northwestern University, Evanston, IL 
Cell Biology, Disease, Molecular Neuroscience, Neurobiology of Disease

108 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Kim S, Coukos R, Gao F, Krainc D. Dysregulation of organelle membrane contact sites in neurological diseases. Neuron. PMID 35561676 DOI: 10.1016/j.neuron.2022.04.020  0.575
2021 Burbulla LF, Zheng J, Song P, Jiang W, Johnson ME, Brundin P, Krainc D. Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson's disease models. Jci Insight. 6. PMID 34622801 DOI: 10.1172/jci.insight.148649  0.321
2021 Brooker SM, Krainc D. Glucocerebrosidase dysfunction in neurodegenerative disease. Essays in Biochemistry. PMID 34528667 DOI: 10.1042/EBC20210018  0.401
2021 Kim S, Wong YC, Gao F, Krainc D. Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson's disease. Nature Communications. 12: 1807. PMID 33753743 DOI: 10.1038/s41467-021-22113-3  0.63
2021 Charif M, Wong YC, Kim S, Guichet A, Vignal C, Zanlonghi X, Bensaid P, Procaccio V, Bonneau D, Amati-Bonneau P, Reynier P, Krainc D, Lenaers G. Dominant mutations in MIEF1 affect mitochondrial dynamics and cause a singular late onset optic neuropathy. Molecular Neurodegeneration. 16: 12. PMID 33632269 DOI: 10.1186/s13024-021-00431-w  0.553
2021 Burbulla LF, Mc Donald JM, Valdez C, Gao F, Bigio EH, Krainc D. Modeling Brain Pathology of Niemann-Pick Disease Type C Using Patient-Derived Neurons. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 33438272 DOI: 10.1002/mds.28463  0.303
2020 Minakaki G, Krainc D, Burbulla LF. The Convergence of Alpha-Synuclein, Mitochondrial, and Lysosomal Pathways in Vulnerability of Midbrain Dopaminergic Neurons in Parkinson's Disease. Frontiers in Cell and Developmental Biology. 8: 580634. PMID 33381501 DOI: 10.3389/fcell.2020.580634  0.35
2020 Tsunemi T, Ishiguro Y, Yoroisaka A, Valdez C, Miyamoto K, Ishikawa K, Saiki S, Akamatsu W, Hattori N, Krainc D. Astrocytes Protect Human Dopaminergic Neurons from α-Synuclein Accumulation and Propagation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 33046546 DOI: 10.1523/JNEUROSCI.0954-20.2020  0.328
2020 Boussaad I, Obermaier CD, Hanss Z, Bobbili DR, Bolognin S, Glaab E, Wołyńska K, Weisschuh N, De Conti L, May C, Giesert F, Grossmann D, Lambert A, Kirchen S, Biryukov M, ... ... Krainc D, et al. A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinson's disease. Science Translational Medicine. 12. PMID 32908004 DOI: 10.1126/Scitranslmed.Aau3960  0.477
2020 Peng W, Wong YC, Krainc D. Mitochondria-lysosome contacts regulate mitochondrial Ca dynamics via lysosomal TRPML1. Proceedings of the National Academy of Sciences of the United States of America. PMID 32703809 DOI: 10.1073/Pnas.2003236117  0.314
2020 Marotta N, Kim S, Krainc D. Organoid and pluripotent stem cells in Parkinson's disease modeling: an expert view on their value to drug discovery. Expert Opinion On Drug Discovery. 1-15. PMID 31899983 DOI: 10.1080/17460441.2020.1703671  0.649
2019 Ysselstein D, Nguyen M, Young TJ, Severino A, Schwake M, Merchant K, Krainc D. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients. Nature Communications. 10: 5570. PMID 31804465 DOI: 10.1038/S41467-019-13413-W  0.457
2019 Burbulla LF, Jeon S, Zheng J, Song P, Silverman RB, Krainc D. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease. Science Translational Medicine. 11. PMID 31619543 DOI: 10.1126/Scitranslmed.Aau6870  0.444
2019 Valdez C, Ysselstein D, Young TJ, Zheng J, Krainc D. Progranulin mutations result in impaired processing of prosaposin and reduced glucocerebrosidase activity. Human Molecular Genetics. PMID 31600775 DOI: 10.1093/Hmg/Ddz229  0.397
2019 Wong YC, Luk K, Purtell K, Burke Nanni S, Stoessl AJ, Trudeau LE, Yue Z, Krainc D, Oertel W, Obeso JA, Volpicelli-Daley LA. Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals? Movement Disorders : Official Journal of the Movement Disorder Society. PMID 31483900 DOI: 10.1002/Mds.27823  0.436
2019 Burbulla LF, Krainc D. The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease. Neurobiology of Disease. 132: 104545. PMID 31351996 DOI: 10.1016/J.Nbd.2019.104545  0.445
2019 Burbulla LF, Krainc D. The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease. Neurobiology of Disease. 132: 104545. PMID 31351996 DOI: 10.1016/j.nbd.2019.104545  0.342
2019 Wong YC, Peng W, Krainc D. Lysosomal Regulation of Inter-mitochondrial Contact Fate and Motility in Charcot-Marie-Tooth Type 2. Developmental Cell. PMID 31231042 DOI: 10.1016/J.Devcel.2019.05.033  0.334
2019 Peng W, Minakaki G, Nguyen M, Krainc D. Preserving Lysosomal Function in the Aging Brain: Insights from Neurodegeneration. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 31183763 DOI: 10.1007/S13311-019-00742-3  0.38
2019 Tsunemi T, Perez-Rosello T, Ishiguro Y, Yoroisaka A, Jeon S, Hamada K, Krishna Vangipuram Suresh M, Wong YC, Xie Z, Akamatsu W, Mazzulli JR, Surmeier DJ, Hattori N, Krainc D. Increased lysosomal exocytosis induced by lysosomal Ca channel agonists protects human dopaminergic neurons from α-synuclein toxicity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 31097622 DOI: 10.1523/Jneurosci.3085-18.2019  0.456
2019 Wong YC, Kim S, Peng W, Krainc D. Regulation and Function of Mitochondria-Lysosome Membrane Contact Sites in Cellular Homeostasis. Trends in Cell Biology. PMID 30898429 DOI: 10.1016/J.Tcb.2019.02.004  0.591
2019 Ysselstein D, Shulman JM, Krainc D. Emerging links between pediatric lysosomal storage diseases and adult parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30726573 DOI: 10.1002/Mds.27631  0.38
2019 Zheng J, Jeon S, Jiang W, Burbulla LF, Ysselstein D, Oevel K, Krainc D, Silverman RB. Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase. Journal of Medicinal Chemistry. PMID 30645117 DOI: 10.1021/Acs.Jmedchem.8B01294  0.431
2019 Kim S, Wong Y, Krainc D. Misregulation of mitochondria–lysosome contact sites in glucocerebrosidase (GBA) Parkinson's patient neurons Ibro Reports. 6: S557. DOI: 10.1016/J.Ibror.2019.07.1751  0.37
2018 Nguyen M, Wong YC, Ysselstein D, Severino A, Krainc D. Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson's Disease. Trends in Neurosciences. PMID 30509690 DOI: 10.1016/J.Tins.2018.11.001  0.438
2018 Trajkovic K, Krainc D. Novel Approach to Tracking Mutant Huntingtin in Biosamples. Trends in Molecular Medicine. 24: 978-981. PMID 30509361 DOI: 10.1016/J.Molmed.2018.10.002  0.431
2018 Trajkovic K, Krainc D. Novel Approach to Tracking Mutant Huntingtin in Biosamples. Trends in Molecular Medicine. 24: 978-981. PMID 30509361 DOI: 10.1016/j.molmed.2018.10.002  0.325
2018 Seibler P, Burbulla LF, Dulovic M, Zittel S, Heine J, Schmidt T, Rudolph F, Westenberger A, Rakovic A, Münchau A, Krainc D, Klein C. Iron overload is accompanied by mitochondrial and lysosomal dysfunction in WDR45 mutant cells. Brain : a Journal of Neurology. PMID 30169597 DOI: 10.1093/Brain/Awy230  0.353
2018 Causevic M, Dominko K, Malnar M, Vidatic L, Cermak S, Pigoni M, Kuhn PH, Colombo A, Havas D, Flunkert S, McDonald J, Gunnersen JM, Hutter-Paier B, Tahirovic S, Windisch M, ... Krainc D, et al. BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains. Plos One. 13: e0200344. PMID 29979789 DOI: 10.1371/Journal.Pone.0200344  0.406
2018 Nguyen M, Krainc D. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. PMID 29735704 DOI: 10.1073/Pnas.1717590115  0.418
2018 Zheng J, Chen L, Skinner OS, Ysselstein D, Remis J, Lansbury P, Skerlj R, Mrosek M, Heunisch U, Krapp S, Charrow J, Schwake M, Kelleher NL, Silverman RB, Krainc D. β-Glucocerebrosidase modulators promote dimerization of β-glucocerebrosidase and reveal an allosteric binding site. Journal of the American Chemical Society. PMID 29676907 DOI: 10.1021/Jacs.7B13003  0.363
2018 Kim MJ, Jeon S, Burbulla LF, Krainc D. Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function. Human Molecular Genetics. PMID 29579237 DOI: 10.1093/Hmg/Ddy105  0.425
2018 Gauthier J, Meijer IA, Lessel D, Mencacci NE, Krainc D, Hempel M, Tsiakas K, Prokisch H, Rossignol E, Helm MH, Rodan LH, Karamchandani J, Carecchio M, Lubbe SJ, Telegrafi A, et al. Recessive mutations in VPS13D cause childhood-onset movement disorders. Annals of Neurology. PMID 29518281 DOI: 10.1002/Ana.25204  0.357
2018 Wong YC, Ysselstein D, Krainc D. Mitochondria-lysosome contacts regulate mitochondrial fission via RAB7 GTP hydrolysis. Nature. PMID 29364868 DOI: 10.1038/Nature25486  0.357
2018 Simuni T, Krainc D. High priority publications on Parkinson's disease in 2017. The Lancet. Neurology. 17: 8-10. PMID 29263010 DOI: 10.1016/S1474-4422(17)30416-7  0.37
2017 Al-Ramahi I, Giridharan SSP, Chen YC, Patnaik S, Safren N, Hasegawa J, de Haro M, Wagner Gee AK, Titus SA, Jeong H, Clarke J, Krainc D, Zheng W, Irvine RF, Barmada S, et al. Inhibition of PIP4Kγ ameliorates the pathological effects of mutant huntingtin protein. Elife. 6. PMID 29256861 DOI: 10.7554/Elife.29123  0.466
2017 Conrad KS, Cheng TW, Ysselstein D, Heybrock S, Hoth LR, Chrunyk BA, Am Ende CW, Krainc D, Schwake M, Saftig P, Liu S, Qiu X, Ehlers MD. Lysosomal integral membrane protein-2 as a phospholipid receptor revealed by biophysical and cellular studies. Nature Communications. 8: 1908. PMID 29199275 DOI: 10.1038/S41467-017-02044-8  0.31
2017 Stojkovska I, Krainc D, Mazzulli JR. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease. Cell and Tissue Research. PMID 29064079 DOI: 10.1007/S00441-017-2704-Y  0.462
2017 Valdez C, Wong YC, Schwake M, Bu G, Wszolek ZK, Krainc D. Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients. Human Molecular Genetics. PMID 29036611 DOI: 10.1093/Hmg/Ddx364  0.386
2017 Völker JM, Dergai M, Abriata LA, Mingard Y, Ysselstein D, Krainc D, Dal Peraro M, Fischer von Mollard G, Fasshauer D, Koliwer J, Schwake M. Functional assays for the assessment of the pathogenicity of variants of GOSR2, an ER-to-Golgi SNARE involved in progressive myoclonus epilepsies. Disease Models & Mechanisms. 10: 1391-1398. PMID 28982678 DOI: 10.1242/Dmm.029132  0.311
2017 Shamir R, Klein C, Amar D, Vollstedt EJ, Bonin M, Usenovic M, Wong YC, Maver A, Poths S, Safer H, Corvol JC, Lesage S, Lavi O, Deuschl G, Kuhlenbaeumer G, ... ... Krainc D, et al. Analysis of blood-based gene expression in idiopathic Parkinson disease. Neurology. PMID 28916538 DOI: 10.1212/Wnl.0000000000004516  0.36
2017 Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, Santos DP, Blanz J, Obermaier CD, Strojny C, Savas JN, Kiskinis E, Zhuang X, Krüger R, Surmeier DJ, ... Krainc D, et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. Science (New York, N.Y.). PMID 28882997 DOI: 10.1126/Science.Aam9080  0.45
2017 Trajkovic K, Jeong H, Krainc D. Mutant huntingtin is secreted via a late endosomal/lysosomal unconventional secretory pathway. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 28821645 DOI: 10.1523/Jneurosci.0118-17.2017  0.406
2017 Wong YC, Krainc D. α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nature Medicine. 23: 1-13. PMID 28170377 DOI: 10.1038/Nm.4269  0.412
2017 Kim MJ, Deng HX, Wong YC, Siddique T, Krainc D. The Parkinson's disease-linked protein TMEM230 is required for Rab8a-mediated secretory vesicle trafficking and retromer trafficking. Human Molecular Genetics. PMID 28115417 DOI: 10.1093/Hmg/Ddw413  0.417
2017 Mc Donald JM, Krainc D. Lysosomal Proteins as a Therapeutic Target in Neurodegeneration. Annual Review of Medicine. 68: 445-458. PMID 28099085 DOI: 10.1146/Annurev-Med-050715-104432  0.406
2016 Chung SY, Kishinevsky S, Mazzulli JR, Graziotto J, Mrejeru A, Mosharov EV, Puspita L, Valiulahi P, Sulzer D, Milner TA, Taldone T, Krainc D, Studer L, Shim JW. Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation. Stem Cell Reports. PMID 27641647 DOI: 10.1016/J.Stemcr.2016.08.012  0.462
2016 Wong YC, Krainc D. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 27619775 DOI: 10.1002/Mds.26802  0.461
2016 Hsieh CH, Shaltouki A, Gonzalez AE, Bettencourt da Cruz A, Burbulla LF, St Lawrence E, Schüle B, Krainc D, Palmer TD, Wang X. Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson's Disease. Cell Stem Cell. PMID 27618216 DOI: 10.1016/J.Stem.2016.08.002  0.447
2016 Zheng J, Chen L, Schwake M, Silverman RB, Krainc D. Design and Synthesis of Potent Quinazolines as Selective β-Glucocerebrosidase Modulators. Journal of Medicinal Chemistry. PMID 27598312 DOI: 10.1021/Acs.Jmedchem.6B00930  0.389
2016 Burbulla LF, Beaumont KG, Mrksich M, Krainc D. Human Neuron Cultures: Micropatterning Facilitates the Long-Term Growth and Analysis of iPSC-Derived Individual Human Neurons and Neuronal Networks (Adv. Healthcare Mater. 15/2016). Advanced Healthcare Materials. 5: 1893. PMID 27511952 DOI: 10.1002/Adhm.201670079  0.322
2016 Mazzulli JR, Zunke F, Tsunemi T, Toker NJ, Jeon S, Burbulla LF, Patnaik S, Sidransky E, Marugan JJ, Sue CM, Krainc D. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 36: 7693-706. PMID 27445146 DOI: 10.1523/Jneurosci.0628-16.2016  0.431
2016 Deng HX, Shi Y, Yang Y, Ahmeti KB, Miller N, Huang C, Cheng L, Zhai H, Deng S, Nuytemans K, Corbett NJ, Kim MJ, Deng H, Tang B, Yang Z, ... ... Krainc D, et al. Identification of TMEM230 mutations in familial Parkinson's disease. Nature Genetics. PMID 27270108 DOI: 10.1038/Ng.3589  0.464
2016 Burbulla LF, Beaumont KG, Mrksich M, Krainc D. Micropatterning Facilitates the Long-Term Growth and Analysis of iPSC-Derived Individual Human Neurons and Neuronal Networks. Advanced Healthcare Materials. PMID 27108930 DOI: 10.1002/Adhm.201500900  0.354
2016 Zunke F, Andresen L, Wesseler S, Groth J, Arnold P, Rothaug M, Mazzulli JR, Krainc D, Blanz J, Saftig P, Schwake M. Characterization of the complex formed by β-glucocerebrosidase and the lysosomal integral membrane protein type-2. Proceedings of the National Academy of Sciences of the United States of America. PMID 27001828 DOI: 10.1073/Pnas.1514005113  0.397
2016 Song P, Trajkovic K, Tsunemi T, Krainc D. Parkin Modulates Endosomal Organization and Function of the Endo-Lysosomal Pathway. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 36: 2425-37. PMID 26911690 DOI: 10.1523/Jneurosci.2569-15.2016  0.446
2016 Domingo A, Amar D, Grütz K, Lee LV, Rosales R, Brüggemann N, Jamora RD, Cutiongco-Dela Paz E, Rolfs A, Dressler D, Walter U, Krainc D, Lohmann K, Shamir R, Klein C, et al. Evidence of TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism. Cellular and Molecular Life Sciences : Cmls. PMID 26879577 DOI: 10.1007/S00018-016-2159-4  0.338
2016 Mazzulli JR, Zunke F, Isacson O, Studer L, Krainc D. α-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proceedings of the National Academy of Sciences of the United States of America. PMID 26839413 DOI: 10.1073/Pnas.1520335113  0.453
2016 Mazzulli JR, Burbulla LF, Krainc D, Ischiropoulos H. Detection of Free and Protein-Bound ortho-Quinones by Near-Infrared Fluorescence. Analytical Chemistry. 88: 2399-405. PMID 26813311 DOI: 10.1021/Acs.Analchem.5B04420  0.366
2016 Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, ... ... Krainc D, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 12: 1-222. PMID 26799652 DOI: 10.1080/15548627.2015.1100356  0.304
2014 Tsunemi T, Hamada K, Krainc D. ATP13A2/PARK9 regulates secretion of exosomes and α-synuclein. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 15281-7. PMID 25392495 DOI: 10.1523/Jneurosci.1629-14.2014  0.374
2014 Rothaug M, Zunke F, Mazzulli JR, Schweizer M, Altmeppen H, Lüllmann-Rauch R, Kallemeijn WW, Gaspar P, Aerts JM, Glatzel M, Saftig P, Krainc D, Schwake M, Blanz J. LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance. Proceedings of the National Academy of Sciences of the United States of America. 111: 15573-8. PMID 25316793 DOI: 10.1073/Pnas.1405700111  0.444
2014 Knight AL, Yan X, Hamamichi S, Ajjuri RR, Mazzulli JR, Zhang MW, Daigle JG, Zhang S, Borom AR, Roberts LR, Lee SK, DeLeon SM, Viollet-Djelassi C, Krainc D, O'Donnell JM, et al. The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's models. Cell Metabolism. 20: 145-57. PMID 24882066 DOI: 10.1016/J.Cmet.2014.04.017  0.399
2014 Sybertz E, Krainc D. Development of targeted therapies for Parkinson's disease and related synucleinopathies. Journal of Lipid Research. 55: 1996-2003. PMID 24668939 DOI: 10.1194/Jlr.R047381  0.415
2014 Bega D, Krainc D. Long-term clinical outcomes after fetal cell transplantation in parkinson disease: implications for the future of cell therapy. Jama. 311: 617-8. PMID 24519302 DOI: 10.1001/Jama.2013.285516  0.32
2014 Tsunemi T, Krainc D. Zn²⁺ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Human Molecular Genetics. 23: 2791-801. PMID 24334770 DOI: 10.1093/Hmg/Ddt572  0.38
2013 Xiang Z, Krainc D. Pharmacological upregulation of PGC1α in oligodendrocytes: implications for Huntington's Disease. Journal of Huntington's Disease. 2: 101-5. PMID 25063433 DOI: 10.3233/Jhd-130046  0.335
2013 Miller JD, Ganat YM, Kishinevsky S, Bowman RL, Liu B, Tu EY, Mandal PK, Vera E, Shim JW, Kriks S, Taldone T, Fusaki N, Tomishima MJ, Krainc D, Milner TA, et al. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell. 13: 691-705. PMID 24315443 DOI: 10.1016/J.Stem.2013.11.006  0.405
2013 Chung CY, Khurana V, Auluck PK, Tardiff DF, Mazzulli JR, Soldner F, Baru V, Lou Y, Freyzon Y, Cho S, Mungenast AE, Muffat J, Mitalipova M, Pluth MD, Jui NT, ... ... Krainc D, et al. Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science (New York, N.Y.). 342: 983-7. PMID 24158904 DOI: 10.1126/Science.1245296  0.481
2013 Vashishtha M, Ng CW, Yildirim F, Gipson TA, Kratter IH, Bodai L, Song W, Lau A, Labadorf A, Vogel-Ciernia A, Troncosco J, Ross CA, Bates GP, Krainc D, Sadri-Vakili G, et al. Targeting H3K4 trimethylation in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. 110: E3027-36. PMID 23872847 DOI: 10.1073/Pnas.1311323110  0.402
2013 Klein C, Krainc D. Glucocerebrosidase mutations: tipping point toward Parkinson disease and dementia? Jama Neurology. 70: 686-8. PMID 23588619 DOI: 10.1001/Jamaneurol.2013.87  0.36
2013 Schultheis PJ, Fleming SM, Clippinger AK, Lewis J, Tsunemi T, Giasson B, Dickson DW, Mazzulli JR, Bardgett ME, Haik KL, Ekhator O, Chava AK, Howard J, Gannon M, Hoffman E, ... ... Krainc D, et al. Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits. Human Molecular Genetics. 22: 2067-82. PMID 23393156 DOI: 10.1093/Hmg/Ddt057  0.451
2013 Rakovic A, Shurkewitsch K, Seibler P, Grünewald A, Zanon A, Hagenah J, Krainc D, Klein C. Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)-dependent ubiquitination of endogenous Parkin attenuates mitophagy: study in human primary fibroblasts and induced pluripotent stem cell-derived neurons. The Journal of Biological Chemistry. 288: 2223-37. PMID 23212910 DOI: 10.1074/Jbc.M112.391680  0.432
2013 Li X, Uemura K, Hashimoto T, Nasser-Ghodsi N, Arimon M, Lill CM, Palazzolo I, Krainc D, Hyman BT, Berezovska O. Neuronal activity and secreted amyloid β lead to altered amyloid β precursor protein and presenilin 1 interactions. Neurobiology of Disease. 50: 127-34. PMID 23064434 DOI: 10.1016/J.Nbd.2012.10.002  0.352
2013 Kumar KR, Ramirez A, Göbel A, Kresojević N, Svetel M, Lohmann K, M Sue C, Rolfs A, Mazzulli JR, Alcalay RN, Krainc D, Klein C, Kostic V, Grünewald A. Glucocerebrosidase mutations in a Serbian Parkinson's disease population. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 20: 402-5. PMID 22812582 DOI: 10.1111/J.1468-1331.2012.03817.X  0.383
2012 Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sundberg M, McLean JR, Carrillo-Reid L, Xie Z, Osborn T, Hargus G, Deleidi M, Lawson T, Bogetofte H, Perez-Torres E, ... ... Krainc D, et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Science Translational Medicine. 4: 141ra90. PMID 22764206 DOI: 10.1126/Scitranslmed.3003985  0.436
2012 Usenovic M, Knight AL, Ray A, Wong V, Brown KR, Caldwell GA, Caldwell KA, Stagljar I, Krainc D. Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity. Human Molecular Genetics. 21: 3785-94. PMID 22645275 DOI: 10.1093/Hmg/Dds206  0.462
2012 Usenovic M, Krainc D. Lysosomal dysfunction in neurodegeneration: the role of ATP13A2/PARK9. Autophagy. 8: 987-8. PMID 22561922 DOI: 10.4161/Auto.20256  0.453
2012 Usenovic M, Tresse E, Mazzulli JR, Taylor JP, Krainc D. Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 4240-6. PMID 22442086 DOI: 10.1523/Jneurosci.5575-11.2012  0.494
2012 Lim MA, Selak MA, Xiang Z, Krainc D, Neve RL, Kraemer BC, Watts JL, Kalb RG. Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 1123-41. PMID 22262909 DOI: 10.1523/Jneurosci.6554-10.2012  0.376
2012 Jiang M, Wang J, Fu J, Du L, Jeong H, West T, Xiang L, Peng Q, Hou Z, Cai H, Seredenina T, Arbez N, Zhu S, Sommers K, Qian J, ... ... Krainc D, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nature Medicine. 18: 153-8. PMID 22179319 DOI: 10.1038/Nm.2558  0.459
2012 Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR, Yates JR, Bordone L, Guarente L, Krainc D. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nature Medicine. 18: 159-65. PMID 22179316 DOI: 10.1038/Nm.2559  0.436
2012 Graziotto JJ, Cao K, Collins FS, Krainc D. Rapamycin activates autophagy in Hutchinson-Gilford progeria syndrome: implications for normal aging and age-dependent neurodegenerative disorders. Autophagy. 8: 147-51. PMID 22170152 DOI: 10.4161/Auto.8.1.18331  0.32
2012 Palada V, Terzić J, Mazzulli J, Bwala G, Hagenah J, Peterlin B, Hung AY, Klein C, Krainc D. Histamine N-methyltransferase Thr105Ile polymorphism is associated with Parkinson's disease. Neurobiology of Aging. 33: 836.e1-3. PMID 21794955 DOI: 10.1016/J.Neurobiolaging.2011.06.015  0.352
2012 Mazzulli J, Krainc D. A Mechanistic Connection Between Gaucher Disease and the Synucleinopathies Molecular Genetics and Metabolism. 105: S46. DOI: 10.1016/J.Ymgme.2011.11.112  0.35
2011 Sadagurski M, Cheng Z, Rozzo A, Palazzolo I, Kelley GR, Dong X, Krainc D, White MF. IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. The Journal of Clinical Investigation. 121: 4070-81. PMID 21926467 DOI: 10.1172/Jci46305  0.385
2011 Cao K, Graziotto JJ, Blair CD, Mazzulli JR, Erdos MR, Krainc D, Collins FS. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Science Translational Medicine. 3: 89ra58. PMID 21715679 DOI: 10.1126/Scitranslmed.3002346  0.345
2011 Xiang Z, Valenza M, Cui L, Leoni V, Jeong HK, Brilli E, Zhang J, Peng Q, Duan W, Reeves SA, Cattaneo E, Krainc D. Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 9544-53. PMID 21715619 DOI: 10.1523/Jneurosci.1291-11.2011  0.33
2011 Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 146: 37-52. PMID 21700325 DOI: 10.1016/J.Cell.2011.06.001  0.481
2011 Park JS, Mehta P, Cooper AA, Veivers D, Heimbach A, Stiller B, Kubisch C, Fung VS, Krainc D, Mackay-Sim A, Sue CM. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism. Human Mutation. 32: 956-64. PMID 21542062 DOI: 10.1002/Humu.21527  0.348
2011 Seibler P, Graziotto J, Jeong H, Simunovic F, Klein C, Krainc D. Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 5970-6. PMID 21508222 DOI: 10.1523/Jneurosci.4441-10.2011  0.46
2011 Klein C, Krainc D, Schlossmacher MG, Lang AE. Translational research in neurology and neuroscience 2011: movement disorders. Archives of Neurology. 68: 709-16. PMID 21320985 DOI: 10.1001/Archneurol.2011.11  0.36
2010 Kegel KB, Sapp E, Alexander J, Reeves P, Bleckmann D, Sobin L, Masso N, Valencia A, Jeong H, Krainc D, Palacino J, Curtis D, Kuhn R, Betschart C, Sena-Esteves M, et al. Huntingtin cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors. Molecular Neurodegeneration. 5: 58. PMID 21156064 DOI: 10.1186/1750-1326-5-58  0.377
2010 Filimonenko M, Isakson P, Finley KD, Anderson M, Jeong H, Melia TJ, Bartlett BJ, Myers KM, Birkeland HC, Lamark T, Krainc D, Brech A, Stenmark H, Simonsen A, Yamamoto A. The selective macroautophagic degradation of aggregated proteins requires the PI3P-binding protein Alfy. Molecular Cell. 38: 265-79. PMID 20417604 DOI: 10.1016/J.Molcel.2010.04.007  0.313
2010 Krainc D. Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases. Archives of Neurology. 67: 388-92. PMID 20385902 DOI: 10.1001/Archneurol.2010.40  0.42
2010 Krainc D. Huntington's disease: tagged for clearance. Nature Medicine. 16: 32-3. PMID 20057421 DOI: 10.1038/Nm0110-32  0.44
2009 Lovrecic L, Kastrin A, Kobal J, Pirtosek Z, Krainc D, Peterlin B. Gene expression changes in blood as a putative biomarker for Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 2277-81. PMID 19844910 DOI: 10.1002/Mds.22477  0.349
2009 Jeong H, Then F, Melia TJ, Mazzulli JR, Cui L, Savas JN, Voisine C, Paganetti P, Tanese N, Hart AC, Yamamoto A, Krainc D. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell. 137: 60-72. PMID 19345187 DOI: 10.1016/J.Cell.2009.03.018  0.418
2008 Savas JN, Makusky A, Ottosen S, Baillat D, Then F, Krainc D, Shiekhattar R, Markey SP, Tanese N. Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies. Proceedings of the National Academy of Sciences of the United States of America. 105: 10820-5. PMID 18669659 DOI: 10.1073/Pnas.0800658105  0.391
2006 Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD, Cui L, Beyer RP, Easley CN, Smith AC, Krainc D, et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metabolism. 4: 349-62. PMID 17055784 DOI: 10.1016/J.Cmet.2006.10.004  0.364
2006 Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 127: 59-69. PMID 17018277 DOI: 10.1016/J.Cell.2006.09.015  0.374
2006 Chen-Plotkin AS, Sadri-Vakili G, Yohrling GJ, Braveman MW, Benn CL, Glajch KE, DiRocco DP, Farrell LA, Krainc D, Gines S, MacDonald ME, Cha JH. Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease. Neurobiology of Disease. 22: 233-41. PMID 16442295 DOI: 10.1016/J.Nbd.2005.11.001  0.341
2005 Zhai W, Jeong H, Cui L, Krainc D, Tjian R. In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell. 123: 1241-53. PMID 16377565 DOI: 10.1016/J.Cell.2005.10.030  0.393
2005 Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, Rosas HD, Hersch SM, Hogarth P, Bouzou B, Jensen RV, Krainc D. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease Proceedings of the National Academy of Sciences of the United States of America. 102: 11023-11028. PMID 16043692 DOI: 10.1073/Pnas.0504921102  0.346
2002 Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL, Woods AM, Chan EY, Kooperberg C, Krainc D, Young AB, Tapscott SJ, Olson JM. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Human Molecular Genetics. 11: 1911-26. PMID 12165554 DOI: 10.1093/Hmg/11.17.1911  0.327
2002 Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, Mouradian MM, Young AB, Tanese N, Krainc D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science (New York, N.Y.). 296: 2238-43. PMID 11988536 DOI: 10.1126/Science.1072613  0.597
2000 Okamoto S, Krainc D, Sherman K, Lipton SA. Antiapoptotic role of the p38 mitogen-activated protein kinase-myocyte enhancer factor 2 transcription factor pathway during neuronal differentiation. Proceedings of the National Academy of Sciences of the United States of America. 97: 7561-6. PMID 10852968 DOI: 10.1073/Pnas.130502697  0.351
1995 Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proceedings of the National Academy of Sciences of the United States of America. 92: 7162-6. PMID 7638161 DOI: 10.1073/Pnas.92.16.7162  0.319
Show low-probability matches.